Selected article for: "CI confidence interval and inflammatory index"

Author: Yang, Boyi; Chang, Xiaoyan; Huang, Jiabao; Pan, Wen; Si, Zhilong; Zhang, Cuntai; Li, Hong
Title: The role of IL-6/lymphocyte ratio in the peripheral blood of severe patients with COVID-19
  • Cord-id: yl8s6hvp
  • Document date: 2021_3_12
  • ID: yl8s6hvp
    Snippet: Background To investigate the prognostic value of a novel immune-inflammatory index, the interleukin-6-to-lymphocyte ratio (IL-6/LY), with the clinical outcomes of severe coronavirus disease 2019 (COVID-19) cases Methods A cohort study of COVID-19 patients in Tongji Hospital, from January 2020 to February 2020, was evaluated. Kaplan–Meier method and the log-rank test was performed to analyze survival data. Univariate and multivariate analyses were performed with COX proportional hazard regress
    Document: Background To investigate the prognostic value of a novel immune-inflammatory index, the interleukin-6-to-lymphocyte ratio (IL-6/LY), with the clinical outcomes of severe coronavirus disease 2019 (COVID-19) cases Methods A cohort study of COVID-19 patients in Tongji Hospital, from January 2020 to February 2020, was evaluated. Kaplan–Meier method and the log-rank test was performed to analyze survival data. Univariate and multivariate analyses were performed with COX proportional hazard regression model. The primary and secondary outcomes were in-hospital mortality and multiple organ dysfunction syndrome (MODS), respectively Results Total 320 adult patients were enrolled in our analyses. Patients were divided into low IL-6/LY group and high IL-6/LY group based on the cutoff value with 2.50. The Kaplan-Meier survival curves showed that high-value group (IL-6/LY≥2.50) had a greater risk of poor prognosis (P<0.001, respectively). Multivariate analysis indicated that IL-6/LY was the independent risk predictor for in-hospital mortality (hazard ratio [HR]=3.404, 95% confidence interval [CI]=1.090-10.633, P=0.035) and MODS development (HR, 4.143; 95%CI, 1.321-12.986, P=0.015). Meanwhile, IL-6/LY was positively correlated with the MuLBSTA score (r=0.137, P=0.031), suggesting that IL-6/LY was associated with long-term mortality (90-day). Furthermore, kinetic analysis revealed that the dynamic changes of inflammatory immune indexes were related to the severity of the disease Conclusions The elevated IL-6/LY was related with the increased risk of poor prognosis. Not only that, IL-6/LY could be used for risk stratification and early clinical identification of high-risk patients

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and admission non icu group: 1
    • acute ards respiratory distress syndrome and admission seven day: 1
    • acute ards respiratory distress syndrome and admission time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and log rank test kaplan meier method: 1
    • acute ards respiratory distress syndrome and long term outcome: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and low lymphocyte count: 1, 2
    • acute dysfunction and admission day: 1, 2, 3, 4
    • acute dysfunction and admission time: 1, 2, 3, 4, 5
    • acute dysfunction and long term outcome: 1
    • acute lung injury and admission day: 1, 2, 3
    • acute lung injury and admission time: 1, 2, 3
    • acute lung injury and long term outcome: 1
    • acute respiratory syndrome and admission non icu group: 1
    • acute respiratory syndrome and admission seven day: 1, 2
    • acute respiratory syndrome and admission time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and log rank test kaplan meier method: 1, 2, 3
    • acute respiratory syndrome and long term outcome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute respiratory syndrome and low level remain: 1
    • acute respiratory syndrome and low lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21